Armetheon to Present at the 14th Annual BIO Investor Forum



Milpitas, CA, October 14, 2015 – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced that Dr. Sanjay Kakkar, Chief Executive Officer, will present a company overview at the 14th Annual BIO Investor Forum at the Parc 55 Hotel on Wednesday, October 21, 2015 at 10:30a.m. Pacific Time in San Francisco, CA.

In addition, Armetheon today announced that the Company will attend the American Heart Association-Scientific Sessions Annual Meeting in Orlando, Florida from November 7-11, 2015.

About Armetheon 

Armetheon, Inc., is a privately held, specialty pharmaceutical company developing and commercializing innovative medicines addressing major unmet needs in cardiovascular disease, initially in thrombosis. Armetheon focuses on improved therapies with the goal of increased efficacy, safety, and utility, targeting specialty markets with clearly defined regulatory pathways. Armetheon’s lead candidate, tecarfarin, is being investigated for use as a Vitamin K Antagonist and is currently in Phase 3 development for the prevention and management of thrombosis. For more information: www.armetheon.com.

Contacts 

For Armetheon:
Heather Lake, Director of Corporate Development
+1 650-646-3898, ext. 121
hlake@armetheon.com

For Media: Justin Jackson
For Investor Inquiries: Ami Bavishi
Burns McClellan
+1 212-213-0006
jjackson@burnsmc.com
abavishi@burnsmc.com